JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Melanotan II represents a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) extensively studied in cell-based assay formats for its broad melanocortin receptor binding properties. This research peptide demonstrates interactions across multiple melanocortin receptor subtypes (MC1R, MC3R, MC4R, MC5R) with distinct binding affinity profiles and downstream signaling cascade activation. Published in vitro research characterizes its molecular interactions, receptor selectivity patterns, and pathway engagement mechanisms in defined cell model systems under controlled laboratory conditions.
Melanotan II exhibits pan-melanocortin receptor agonist activity through direct binding interactions with MC1R, MC3R, MC4R, and MC5R subtypes. In vitro radioligand binding assays demonstrate nanomolar affinity constants across these receptor populations, with particularly high selectivity for MC1R and MC4R subtypes in transfected cell expression systems. Competitive binding studies utilizing [125I]-labeled native ligands reveal displacement characteristics consistent with high-affinity receptor occupation.
The peptide structure contains key pharmacophore elements essential for melanocortin receptor recognition, including the critical His-Phe-Arg-Trp tetrapeptide sequence derived from the native α-MSH template. Cyclization between cysteine residues enhances binding stability and receptor selectivity compared to linear analogs in comparative cell-based assays.
Primary signaling transduction occurs through Gαs protein-coupled adenylyl cyclase activation, resulting in elevated intracellular cyclic adenosine monophosphate (cAMP) concentrations. In vitro cAMP accumulation assays utilizing forskolin controls demonstrate dose-dependent second messenger generation following melanotan II receptor binding. Time-course studies in MC1R-expressing cell lines reveal peak cAMP responses within 15-30 minutes of peptide application.
Downstream cAMP-dependent protein kinase A (PKA) phosphorylation cascades activate cAMP response element-binding protein (CREB) transcription factors, ultimately driving melanogenic enzyme expression in appropriate cell model systems.
MC1R signaling cascades regulate tyrosinase enzyme activity through multiple convergent pathways in melanocyte cell models. cAMP-dependent transcriptional activation increases tyrosinase gene expression, while PKA-mediated phosphorylation events modulate enzyme kinetic parameters. In vitro tyrosinase activity assays demonstrate enhanced L-DOPA oxidation rates following melanotan II treatment in B16 melanoma cell cultures.
Additional melanogenic enzymes including tyrosinase-related protein 1 (TRP-1) and dopachrome tautomerase (DCT/TRP-2) show coordinated upregulation through shared cAMP-responsive transcriptional mechanisms. Quantitative PCR analysis reveals synchronized mRNA expression increases across the complete melanogenic enzyme cascade.
Microphthalmia-associated transcription factor (MITF) serves as the master regulator of melanogenic gene expression programs activated by MC1R signaling. In vitro studies demonstrate CREB-mediated MITF promoter activation following cAMP elevation in melanocyte cell models. ChIP-seq analysis reveals MITF binding to conserved E-box motifs within tyrosinase and TRP gene regulatory regions.
MITF protein stability and nuclear localization increase substantially following melanotan II treatment, as demonstrated through immunofluorescence microscopy and subcellular fractionation experiments in appropriate cell culture systems.
MC4R-expressing neuronal cell lines demonstrate robust cAMP responses to melanotan II application with distinct kinetic profiles compared to peripheral melanocyte systems. Patch-clamp electrophysiology reveals altered ion channel conductances consistent with PKA-dependent phosphorylation of voltage-gated calcium channels in GT1-7 hypothalamic cell cultures.
Calcium imaging studies show coordinated intracellular calcium oscillations following melanotan II receptor activation, suggesting complex second messenger crosstalk mechanisms beyond direct cAMP signaling pathways.
Saturation binding experiments reveal melanotan II Kd values in the low nanomolar range across melanocortin receptor subtypes, with MC1R and MC4R showing highest binding affinity in transfected CHO cell expression systems. Association and dissociation rate constants indicate relatively slow off-kinetics contributing to prolonged receptor occupancy compared to native α-MSH ligand.
Structure-activity relationship studies utilizing melanotan II analogs demonstrate critical amino acid residues required for optimal receptor binding and functional activity across different melanocortin receptor populations.
Melanotan II represents a valuable research tool for investigating melanocortin receptor pharmacology across multiple cell model systems. Its broad receptor binding profile and potent cAMP signaling activation make it particularly useful for studying MC1R-mediated melanogenesis pathways and MC4R signaling mechanisms in appropriate in vitro experimental contexts. The peptide's high binding affinity and prolonged receptor occupancy characteristics provide advantages for sustained pathway activation studies in controlled laboratory environments.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.